Company is executing on key milestones with CNTY-813 progressing toward IND submission on competitive timeline, strong cash position ($217M runway into 1Q 2029), reduced operating expenses while maintaining pipeline advancement, and positive preclinical data demonstrating durable glucose control and immune protection. Upcoming ADA presentation and CNTY-308 advancement add to positive momentum.
Articles that tag IPSC but are mainly about other companies.
CNTY-101 is listed as a pipeline candidate for CLE, but no specific clinical data or development milestones mentioned.
Advancing CNTY-101, a CD19 CAR-NK cell therapy in Phase I, representing cutting-edge cell-based immunotherapy approach.
Represents the better-capitalized end of the cell-therapy spectrum with ~$117 million in cash and investments, plus a $135 million private placement extending runway into 2029. The stronger balance sheet allows the company to advance similar scientific approaches with greater financial stability.
Articles and sentiment ratings from Massive / Polygon. Sentiment is the provider's model rating for this company, not Gainbot's view.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology
